News

10.9.2020
Press Release

TOPADUR starts clinical development of a new wound healing drug

TOPADUR Pharma AG announces dosing of first healthy subjects in Phase 1 clinical trial of TOP-N53.

Read more
3.7.2020
Press Release

Dr. Daniel L. Vasella new member of the Board of Directors

The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.

Read more
20.5.2020
News

Scientific Publication in the Journal of Investigative Dermatology

A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Promotes Wound Healing in Normal and Diabetic Mice.

Read more

Media Contact

Dr. Paola Atzei

Chief Project Officer & Communications
TOPADUR Pharma AG
Grabenstrasse 11A
8952 Schlieren, Switzerland
paola.atzei@topadur.com+41 44 755 44 63

Investors

InvestorsNews & EventsPresentations & Documents

About us

VisionHistoryLeadershipBoard of DirectorsResearch Partners

Pipeline

Wound HealingSkin FibrosisOphthalmologyMedical cosmetics
OncologyLung Fibrosis
‍

Contact

info@topadur.com+41 44 755 44 66
Topadur Pharma AG
Grabenstrasse 11A
8952 Schlieren, Switzerland
ImpressumLegal Disclaimer